Nirmacom 150 mg, 100 mg FC Tablets
PDF Leaflet Revision Date: 24 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of COVID-19 in adults at risk for severe disease.
Dosage (summary)
300 mg nirmatrelvir (2 tablets) and 100 mg ritonavir (1 tablet) twice daily for 5 days.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding should be discontinued during treatment and for 7 days after.
Key Drug Interactions
- CYP3A inhibitors
- CYP3A inducers
- Colchicine
Contraindications
- Hypersensitivity to components
- Severe hepatic impairment
- Severe renal impairment
Common side effects
- Dysgeusia
- Diarrhoea
- Vomiting
Counselling Points
- Take with or without food, swallow whole.
- Use effective contraception during treatment.
- Monitor for adverse reactions.
Serious warnings
- Risk of serious adverse reactions due to drug interactions
- Hepatotoxicity
- Potential for HIV-1 resistance development
Important Disclaimer
The Nirmacom 150 mg, 100 mg FC Tablets professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
